

# Adam I Marcus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7412563/publications.pdf>

Version: 2024-02-01

24  
papers

1,230  
citations

471509

17  
h-index

580821

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2678  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion. <i>Clinical Cancer Research</i> , 2018, 24, 420-432.	7.0	175
2	The OncoPPI network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies. <i>Nature Communications</i> , 2017, 8, 14356.	12.8	151
3	Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 11569-11577.	3.4	149
4	The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. <i>Cancer Research</i> , 2005, 65, 3883-3893.	0.9	101
5	FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. <i>Oncotarget</i> , 2015, 6, 4757-4772.	1.8	101
6	Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. <i>Journal of Biological Chemistry</i> , 2016, 291, 9991-10005.	3.4	73
7	uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection. <i>Theranostics</i> , 2014, 4, 106-118.	10.0	69
8	LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1883-1886.	1.1	63
9	Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. <i>Oncotarget</i> , 2016, 7, 43124-43149.	1.8	52
10	Epigenetically heterogeneous tumor cells direct collective invasion through filopodia-driven fibronectin micropatterning. <i>Science Advances</i> , 2020, 6, eaaz6197.	10.3	41
11	Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. <i>JCI Insight</i> , 2017, 2, e90487.	5.0	36
12	LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated. <i>Genes and Diseases</i> , 2014, 1, 64-74.	3.4	34
13	A role for activated Cdc42 in glioblastoma multiforme invasion. <i>Oncotarget</i> , 2016, 7, 56958-56975.	1.8	32
14	Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics. <i>Scientific Reports</i> , 2017, 7, 39498.	3.3	30
15	LKB1 kinase-dependent and -independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion. <i>Molecular Biology of the Cell</i> , 2016, 27, 1069-1084.	2.1	26
16	Genetic heterogeneity within collective invasion packs drives leader and follower cell phenotypes. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	23
17	Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC. <i>PLoS ONE</i> , 2014, 9, e107124.	2.5	21
18	Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression. <i>Lung Cancer</i> , 2015, 88, 131-138.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer, 2018, 123, 36-43.	2.0	11
20	Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis. Molecular Cancer Therapeutics, 2021, 20, 274-283.	4.1	9
21	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PLoS ONE, 2019, 14, e0206309.	2.5	7
22	LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions. Oncotarget, 2016, 7, 2519-2531.	1.8	7
23	RhoA, a novel tumor suppressor or oncogene as a therapeutic target?. Genes and Diseases, 2015, 2, 2-3.	3.4	5
24	Energizing the Search to Target LKB1-Mutant Tumors. Cancer Discovery, 2013, 3, 843-845.	9.4	2